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Abstract
Because of its effect on insulin, carbohydrate restriction is one of the obvious dietary choices for
weight reduction and diabetes. Such interventions generally lead to higher levels of dietary fat than
official recommendations and have long been criticized because of potential effects on
cardiovascular risk although many literature reports have shown that they are actually protective
even in the absence of weight loss. A recent report of Krauss et al. (AJCN, 2006) separates the
effects of weight loss and carbohydrate restriction. They clearly confirm that carbohydrate
restriction leads to an improvement in atherogenic lipid states in the absence of weight loss or in
the presence of higher saturated fat. In distinction, low fat diets seem to require weight loss for
effective improvement in atherogenic dyslipidemia.
Background
The recent report of Krauss et al. [1] highlights the rather
dramatic differences in the effects of carbohydrate
restricted (CR) and low fat (LF) diets on the lipid changes
that may predispose to atherosclerosis. By first imple-
menting weight maintenance diets of different composi-
tions followed by calorie reduction, the authors show that
significant improvement in atherogenic lipid states (lower
TAG, higher HDL, lower apoB/apoA-1) can be brought
about by CR even in the absence of weight loss or in the
presence of higher saturated fat. When weight loss was fur-
ther implemented in the CR groups, there was little fur-
ther improvement in most markers although HDL
continued to increase on calorie reduction. The LF diet, in
distinction, required weight loss for effective improve-
ment in the lipid profile, and the additive outcome of diet
change and calorie reduction were not as effective as in the
CR diets. These results have obvious implications for
choice of diets and represents a philosophical reversal of
the practical implications of macronutrient composition.
Criticism of the use of CR for weight loss has traditionally
focused on the potential effect on risk of CVD because of
the substitution of fat for carbohydrate. It is now clear that
such a change is beneficial and the demonstration that
actual weight loss is not required for the benefits of CR
suggests the need for reevaluation of current guidelines.
In general, reports on the effects of CR diets continue to
defy conventional wisdom. While most official agencies
recommend limiting dietary fat or at least saturated fat,
experimental data show that replacement of fat, even sat-
urated fat with carbohydrate is deleterious to markers for
atherogenic dyslipidemia [2]. Although several studies in
the literature had pointed to the value of replacing dietary
carbohydrate with fat or protein [3-6], an historical turn-
ing point in the reappraisal of CR diets might be consid-
ered the study of Foster et al. [7] comparing the Atkins diet
with a LF diet. The results were unexpected in that CR,
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which was anticipated to be deleterious was, in fact, ben-
eficial compared to fat reduction. Studies of CR continue
to show improvements in atherogenic dyslipidemia
[5,8,9] and there is an evolving picture that the effects of
CR, notably in lowering insulin and thereby changing
metabolic regulation of lipid, may be more important
than the total amount of lipid substrate.
Atherogenic dyslipidemia
The level of LDL cholesterol is generally considered the
most clinically useful marker for cardiovascular disease
(CVD) and there seems little question that reduction in
LDL, especially if effected by administration of statins, is
accompanied by substantial reduction in the risk of cardi-
ovascular events. The importance of LDL as a primary
marker, however, must be tempered by observations that
LDL is not homogeneous and atherogenicity appears to be
a function of particle size: small dense LDL particles are
more atherogenic [10]. In addition, other risk factors,
high triglyceride (TAG), low HDL, and insulin resistance
are frequently increased under conditions that lower LDL
[8]. The atherogenicity of a greater number of small LDL
particles is reflected in an increase in apolipoprotein B
(apoB) since each atherogenic lipoprotein particle con-
tains one molecule of apoB and total LDL would bias
results towards lower risk. Barter et al. [11] summarized
evidence that apoB is a more reliable indicator of risk than
LDL and further that the apoB/apoA-I ratio is superior to
conventional cholesterol ratios. Finally, circulating TAG is
of considerable importance in this discussion because it is
mechanistically linked to the formation of atherogenic
particles, and is highly sensitive to dietary manipulation.
Study synopsis
Details of the dietary intervention of Krauss et al. [1] are
shown in Table 1. Diets were consumed over 3 sequential
periods in which energy was prescribed to achieve weight
maintenance (3 wk), weight loss (-1000 kcal/day; 5 wk),
and weight stabilization (4 wk). Blood measures were
reported at baseline, after weight maintenance and after
weight loss + stabilization. For comparison, the protocol
from Sharman, et al. [12] for six weeks on a very low car-
bohydrate ketogenic diet (VLCKD) designed for weight
maintenance are also shown in Table 1.
Figures 1, 2, 3, 4, 5 show the results of sequential change
in macronutrient composition and caloric restriction.
Effect of dietary interventions on reduction in TAG Figure 1
Effect of dietary interventions on reduction in TAG. 
Solid Lines : Data from Reference [1] was converted from 
reported log values in their Table 2 and per cent of baseline 
calculated. At week 3, a 1000 kcal reduction in energy was 
implemented and at week 9, dieters were put on mainte-
nance diet. Combined effect of calorie reduction and mainte-
nance are reported at week 12. Dashed line: Data from 
reference [12]: A eucaloric ketogenic diet was instituted for 
six weeks (no weight loss phase). Points were recorded at 
week 3 and 6.
Table 1: Macronutrient composition of diet.  Diet composition from the indicated references.
Group % CHO % FAT % Protein % SF
Krauss – Ref. [1]
LF 54 30 16 7
CR (39 % CHO) 39 29 29 8
CR (26 % CHO) 26 46 29 9
C R  ( 2 6  %  C H O  +  S F ) 2 64 52 91 5
Sharman – Ref [12]
Low Carbohydrate 
Ketogenic (LCKD)
8 6 13 01 1
L F  ( C o n t r o l ) 5 92 51 5 8Nutrition & Metabolism 2006, 3:24 http://www.nutritionandmetabolism.com/content/3/1/24
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Overall, the data show a significantly greater improve-
ment in lipid profile as carbohydrate is reduced even if
this change is not accompanied by caloric reduction and
even in the presence of relatively high saturated fat, in
agreement with results of Sharman, et al. [12]. Data from
Sharman's study is indicated by dotted lines in Figures 2
and 5. When caloric restriction is introduced after these
weight stable changes, there is little additional change in
most parameters on the CR diets, but the additive effects
of the CR and caloric reduction are greater than the addi-
tive effects of fat reduction followed by caloric restriction
(e.g., compare week Wk 12 values for the 56% CHO to the
26% CHO + SF diets in Figures 1, 2, 3, 4, 5).
Mechanisms and the separation of carbohydrate 
restriction and weight loss
The striking data tabulated by Krauss, et al. [1] and pre-
sented in graphic form in Figures 1, 2, 3, 4, 5 are some-
what at odds with their stated conclusion: "Moderate
carbohydrate restriction and weight loss provide equiva-
lent but non-additive approaches to improving athero-
genic dyslipidemia" and "the beneficial lipid changes
resulting from a reduced carbohydrate intake were not sig-
nificant after weight loss."
It is not clear what is meant by additive since the com-
bined effects due to macronutrient change and caloric
restriction are not compared to experiments where they
are implemented together which are known to provide
large positive effects. In any case, at least HDL values do
show significant increases in both phases of the experi-
ment, positive for low carbohydrates, initially negative
and then positive for low fat and there is a pronounced
additive effect (Figure 2).
Compared to weight loss on a LF diet, the high saturated
fat CR diet with no weight loss resulted in better improve-
ments in LDL peak size, TAG, HDL, and the ratios total
cholesterol/HDL and apoB/ApoA-1, that is, the effects are
not equivalent; CR is significantly better than weight loss
in the presence of LF for atherogenic dyslipidemia. The
fact that these effects are not equivalent is further shown
in Figures 1, 2, 3, 4, 5, where the combined (weight stable
and weight loss) effects for LF are not as great as for CR.
The results suggest that if, at week 12, a 26 % CR with sat-
urated fat were instituted for the LF group, further
improvement in lipid profile would be brought about.
Krauss et al. [1] make the underlying assumption that
weight loss is the same whether caused by caloric restric-
tion in the presence of low carbohydrate or low fat but
their data show that this is not so. It seems that they also
Change in the ratio of total cholesterol to HDL with diet Figure 3
Change in the ratio of total cholesterol to HDL with 
diet. The effect is largely due to HDL increases (Figure 2) 
since the total changes in LDL were -11.5, -1.8, -6.9 for 
decreasing carbohydrate. LDL for 26% CHO + SF changed 
little (+0.4).
Change in HDL with diet Figure 2
Change in HDL with diet. Data from reference [1]. 
Extrapolated lines are drawn to indicate that there is a 
greater change during the weight loss phase on low carbohy-
drate diets with or without saturated fat than on the low fat 
diet, that is, carbohydrate restriction improves HDL during 
the macronutrient change and also additively during weight 
loss.Nutrition & Metabolism 2006, 3:24 http://www.nutritionandmetabolism.com/content/3/1/24
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assume that weight loss is a cause not an effect (due to cal-
orie reduction). Whereas this may play a role, it is reason-
able to assume that improvement in dyslipidemia and
weight loss are parallel responses  to calorie reduction
which is the major physiologic stimulus. It is obvious that
the reason lipid changes are not brought about in Krauss's
experiment by weight loss in the low carbohydrate arms is
that the lipid markers have already changed drastically.
Finally, it should be pointed out that the reduction in cal-
ories that is effective in the weight loss phase of the low fat
arm included a substantial reduction in carbohydrate as
one component.
Summary
Although some effort is required to disentangle the data
and interpretation, the recent publication from Krauss et
al. [1] should be recognized as a breakthrough. Their find-
ings, presented in Figures 1, 2, 3, 4, 5 make it clear that the
salutary effects of CR on dyslipidemia do not require
weight loss, a benefit that is not a feature of strategies
based on fat reduction. As such, Krauss et al. [1] provides
one of the strongest arguments to date for CR as a funda-
mental approach to diet, especially for treating athero-
genic dyslipidemia.
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